Request Demo

Last update 28 Feb 2026

Chlorthalidone

Last update 28 Feb 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

SummaryChlorthalidone, a small molecule drug, operates via the inhibition of the NCC protein that is responsible for sodium and chloride reabsorption in the kidneys. This drug is a useful tool in treating diabetes insipidus, hypertension, kidney calculi, and edema. Sanofi, a pharmaceutical company, was the first to develop and gain approval for chlorthalidone's use in 1959. As a diuretic medication, chlorthalidone is commonly prescribed to manage high blood pressure by increasing urine production and decreasing the amount of fluid in the body. Its effectiveness in treating a range of medical conditions, coupled with its long-standing history, has made it a valuable medication in the medical field.

Drug Type

Small molecule drug

Synonyms

1-keto-3-(3'-sulfamyl-4'-chlorophenyl)-3-hydroxyisoindoline, 1-oxo-3-(3-sulfamyl-4-chlorophenyl)-3-hydroxyisoindoline, 2-chloro-5-(1-hydroxy-3-oxo-1-isoindolinyl)benzenesulfonamide

+ [17]

Target

NCC

Action

inhibitors

Mechanism

NCC inhibitors(Thiazide-sensitive sodium-chloride cotransporter inhibitors)

Therapeutic Areas

Nervous System DiseasesCardiovascular DiseasesEndocrinology and Metabolic Disease+ [2]

Active Indication

Diabetes InsipidusEdemaHypertension+ [1]

Inactive Indication-

Originator Organization

Sanofi

Active Organization

Casper Pharma LLC

Chengdu First Pharmaceutical Co. Ltd.

PRM Pharma, LLC

Inactive Organization

Sanofi-Aventis U.S. LLC

License Organization-

Drug Highest PhaseApproved

First Approval Date

United States (07 Apr 1960),

Hypertension

Regulation-

Structure/Sequence

Molecular FormulaC14H11ClN2O4S

InChIKeyJIVPVXMEBJLZRO-UHFFFAOYSA-N

CAS Registry77-36-1

Clinical Trials associated with Chlorthalidone

NCT07238400

/ Not yet recruitingPhase 2IIT

Cardiac Effects of Mineralocorticoid Receptor Antagonism After Preeclampsia

The goal of this clinical trial is to determine if the medication eplerenone yields greater improvements in coronary microvascular function than chlorthalidone in women who experienced preeclampsia during pregnancy and subsequently developed chronic hypertension. The main Aims are:
* To test the hypothesis that, in women with prior preeclampsia, current chronic hypertension, and concentric LV remodeling, eplerenone improves coronary microvascular function vs. chlorthalidone.
* To test the hypothesis that, in women with prior preeclampsia, current chronic hypertension, and concentric LV remodeling, eplerenone improves cardiac structure and function vs. chlorthalidone.
Participants will:
* First receive pre-treatment with Amlodipine for 12 weeks prior to beginning the study medication.
* Start study treatment which involves daily self-administration of two oral capsules (eplerenone + potassium placebo or chlorthalidone + potassium), each taken once a day, for a total of 336 doses over 48 weeks.
* Attend study visits at weeks 2, 12, 24, 36, and 48. These visits will involve collecting information, measuring blood pressure, and gathering blood and urine samples. Echocardiography (cardiac ultrasound), eye exam, and cardiac PET/CT scan will be performed during the baseline and week 48 visits.

Start Date01 Dec 2025

Sponsor / Collaborator

The Massachusetts General Hospital

[+2]

NCT07225764

/ RecruitingPhase 4IIT

Empiric vs Selective Medical Therapy for Calcium Oxalate Stone Prevention: A Randomized Controlled Trial

This single-center randomized controlled trial at Mount Sinai West will enroll 80 patients undergoing percutaneous nephrolithotomy for calcium oxalate stones. Participants will be randomized to receive either empiric therapy or selective therapy guided by 24-hour urine evaluation. The primary outcome is change in calcium oxalate supersaturation at 4 weeks, aiming to determine whether empiric therapy can provide outcomes comparable to selective therapy while simplifying access to prevention.

Start Date23 Oct 2025

Sponsor / Collaborator

Icahn School of Medicine at Mount Sinai

CTRI/2025/06/089242

/ Not yet recruitingNot ApplicableIIT

A Comparative Study of Gokshuradi Kwatha and Chlorthalidone in the Management of Essential Hypertension - NIL

Start Date30 Jun 2025

Sponsor / Collaborator-

100 Clinical Results associated with Chlorthalidone

100 Translational Medicine associated with Chlorthalidone

100 Patents (Medical) associated with Chlorthalidone

2,098

Literatures (Medical) associated with Chlorthalidone

03 Feb 2026·Journal of the American Heart Association

Per‐Protocol Analysis of Chlorthalidone Versus Hydrochlorothiazide for Cardiovascular Event Prevention—Diuretic Comparison Project

Article

Author: Glassman, Peter A. ; Taylor, Addison A. ; Davenport, Michael J. ; Ferguson, Ryan E. ; Cushman, William C. ; Ishani, Areef ; Leatherman, Sarah M. ; Hau, Cynthia ; Lew, Robert A. ; Anand, Sonia T.

Background:

The DCP (Diuretic Comparison Project), a pragmatic trial, evaluated whether chlorthalidone compared with hydrochlorothiazide would reduce the risk of nonfatal cardiovascular disease or noncancer‐related death. The intent‐to‐treat analysis found no difference in such comparison (hazard ratio, 1.04 [95% CI, 0.94–1.16]). The objective of the current study is to estimate the per‐protocol effect of chlorthalidone (12.5/25 mg daily) compared with hydrochlorothiazide (25/50 mg daily) in preventing major adverse cardiovascular events among older patients with hypertension.

Methods:

The effect of adhering to treatment strategies was assessed by censoring at first instance of nonadherence, defined as a gap (>90‐day gap in drug coverage), switch (switching between study medications), and discontinuation (stop taking chlorthalidone/hydrochlorothiazide altogether for >90 days before the end of the study). The primary outcome was a composite of nonfatal myocardial infarction, stroke, heart failure resulting in hospitalization, urgent coronary revascularization for unstable angina, and noncancer‐related death. Using inverse probability weighting, we evaluated the per‐protocol effect of chlorthalidone and hydrochlorothiazide using DCP trial data.

Results:

Nonadherence was found in 5476 (40%) participants; among 8047 (60%) adherents, 3905 (49%) were randomized to chlorthalidone and 4142 (51%) to hydrochlorothiazide. After censoring time when participants deviated from the assigned treatments, the estimated 5‐year risk ratio of the composite primary outcome of nonfatal cardiovascular disease and noncancer‐related death was 1.36 (95% CI, 0.96–2.12) in chlorthalidone compared with hydrochlorothiazide.

Conclusions:

The per‐protocol analysis indicated a lower risk with hydrochlorothiazide compared with chlorthalidone in preventing nonfatal cardiovascular disease and noncancer‐related death; however, this difference was not statistically significant using dispensation data to identify adherence.

Registration:

URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02185417.

01 Jan 2026·Clinical Pharmacology in Drug Development

Pharmacokinetic Interaction Among Amlodipine, Losartan, and Chlorthalidone after a Single Oral Administration in Healthy Male Subjects

Article

Author: Lim, Yirang ; Hong, Sung Hee ; Moon, Seol Ju ; Chung, Jae‐Yong

Abstract:

Antihypertensive drugs are more potent when administered in combinations of two or three different classes of drugs. The objective of this study was to evaluate the pharmacokinetic interaction among amlodipine, losartan, and chlorthalidone. A randomized, open‐label, four‐sequence, four‐period, four‐treatment, single‐dose study was conducted in healthy Korean male subjects, with oral administrations of two tablets of amlodipine 5 mg, one tablet of losartan 100 mg, one tablet of chlorthalidone 25 mg, or co‐administration of all three investigational products. Plasma drug concentrations were measured by liquid chromatography/tandem mass spectrometry. Twenty‐six subjects completed the study. The geometric mean ratios and 90% confidence intervals of C max and AUC last, respectively, were 1.0928 (1.0412‐1.1469) and 1.0360 (0.9958‐1.0778) for amlodipine; 1.1016 (0.9136‐1.3284) and 1.1606 (1.0885‐1.2375) for losartan; 1.0720 (1.0119‐1.1356) and 1.0902 (1.0350‐1.1148) for EXP3174 (active metabolite of losartan); and 0.9462 (0.8626‐1.0379) and 1.0266 (0.9752‐1.0807) for chlorthalidone. All the treatments were well tolerated overall. Besides the slight increase in losartan C max , the combination therapy did not show clinically significant pharmacokinetic interactions in terms of systemic drug exposure.

01 Dec 2025·JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS

LC–MS/MS-based simultaneous quantification of chlorthalidone and cilnidipine in rat plasma: Pharmacokinetic evaluation, green analytical assessment, and DoE-driven optimization

Article

Author: Gandu, Sravanthi ; Gandla, Kumaraswamy ; Repudi, Lalitha

A highly sensitive and reproducible liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was systematically developed and optimized using a Quality by Design (QbD) framework for the simultaneous quantification of chlorthalidone and cilnidipine in rat plasma. Critical method variables-organic phase composition, flow rate, and mobile phase pH-were identified through risk assessment and subsequently optimized via Box-Behnken Design to ensure analytical robustness. Optimal chromatographic conditions comprised 20 % organic content, a flow rate of 1.0 mL/min, and a mobile phase pH of 3.0, facilitating efficient resolution of both analytes. Detection was achieved in positive electrospray ionization mode using multiple reaction monitoring, with transitions of m/z 339.8909 → 85.0951 for chlorthalidone, m/z 493.5237 → 300.1587 for cilnidipine, and m/z 515.6423 → 342.6158 for telmisartan, employed as the internal standard. Method validation, performed in accordance with European Medicines Agency (EMA) guidelines, demonstrated excellent linearity (r² > 0.998), accuracy, and precision, with coefficient of variation consistently <10 %. The method exhibited strong analyte stability and was successfully applied to the pharmacokinetic evaluation of both drugs in Wistar rats. This DoE-optimized LC-MS/MS platform offers a selective, reliable, and environmentally conscious analytical solution for the preclinical assessment of chlorthalidone and cilnidipine.

News (Medical) associated with Chlorthalidone

18 Dec 2025

·pharma.economictimes.indiatimes.com

11% jump in cardiac medicine sales in Gujarat reflects changing treatment strategy

Ahmedabad: The sale of drugs related to cardiovascular diseases (CVD) in Gujarat grew by 11% year-on-year as of Nov, driven by a rise in cardiovascular episodes. However, what is more alarming is that a shift in the way CVDs are being treated to prevent long-term complications has also contributed significantly to this growth. Data from Pharmarack indicates that the moving annual total (MAT) for cardiac therapy drugs increased to Rs 1,731 crore in Nov, up from Rs 1,557 crore in the same month last year. The growth, according to molecule-level sales reflected in the data and medical practitioners' views, has been anchored in chronic risk control rather than acute, event-led therapy. For cardiac therapy, anti-hypertensives and lipid-lowering drugs together now account for well over 70% of the total cardiac therapy sales value. Anti-hypertensives remain the single largest contributor at over Rs 830 crore MAT, followed by lipid-lowering agents at around Rs 420 crore. The sharpest shift in prescriptions has been visible in hypertension management. Between 2021 and 2025, doctors have moved decisively away from single-drug therapy towards combination treatments. Data suggests that telmisartan-based combinations now dominate, commonly paired with amlodipine, beta-blockers such as metoprolol, or diuretics like chlorthalidone. Dual-drug combinations have become routine even for relatively early-stage patients, while triple fixed-dose combinations — once largely restricted to resistant hypertension — are being deployed much earlier. Putting this in perspective, Dr Zeeshan Mansuri, interventional cardiologist at Narayana Hospital, Rakhial, Ahmedabad, said, "The shift in prescription patterns is largely driven by the availability of fixed-dose combinations of antihypertensive, lipid-lowering, and other cardiac medications. Since cardiovascular disease has a multifactorial etiology, most patients require a combination of drug classes to manage heart failure, heart attacks, and atherosclerotic risk factors effectively. This approach is increasingly being adopted earlier in the treatment journey, rather than being reserved only for advanced disease or post-cardiac events." Meanwhile, reliance on standalone ACE inhibitors and older beta-blockers has steadily declined. The prescription message is clear — physicians are no longer waiting for treatment failure. Blood pressure control is being tightened earlier, with a view to preventing downstream cardiac and renal complications. "Combination therapies allow clinicians to achieve better control of blood pressure and lipid levels while improving patient compliance by reducing pill burden. The growing use of these combinations reflects a shift toward more comprehensive and preventive cardiac care, aimed at reducing complications, hospitalisations, and disease progression over time," Dr Mansuri further added. Lipid management shows a similar evolution. Rosuvastatin has overtaken atorvastatin as the leading statin by value, while combination therapies are growing faster than statins alone. Prescriptions increasingly feature statins paired with aspirin, clopidogrel, ezetimibe, or fibrates, signalling a stronger focus on achieving defined LDL-cholesterol targets. Dr Shalin Thakore, consultant cardiologist with Shalby Hospitals, said that cardiac issues often occur alongside other conditions such as diabetes, coronary artery disease (CAD), and hypertension. "Even today, treatment often starts with monotherapy — the primary purpose is to achieve a specific target, such as lowering blood pressure to a certain level. Once that level is achieved, clinicians decide to introduce multiple drugs depending on the case's requirements. Better outcomes in preventing disease onset and managing existing conditions are also factors in choosing multi-drug therapy," he added.

AHA

07 Nov 2025

·www.prnewswire.com

PRM Pharma Announces Nationwide Availability of HemiClor® (Chlorthalidone) 12.5 mg: The First FDA-Approved Low-Dose Chlorthalidone Tablet Aligned With Hypertension Guidelines

WEST CONSHOHOCKEN, Pa., Nov. 7, 2025 /PRNewswire/ -- PRM Pharma, LLC announces the nationwide availability of HemiClor® (chlorthalidone) 12.5 mg tablets, the first and only FDA-approved 12.5 mg formulation of chlorthalidone for the treatment of hypertension in adults ().1 This milestone comes as the newly released 2025 AHA/ACC Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults reemphasizes chlorthalidone's role as a long-acting, thiazide-like diuretic and recommends to "Maximize Diuretic Therapy" by replacing hydrochlorothiazide (HCTZ) with chlorthalidone 12.5 mg or 25 mg in patients with resistant hypertension. 2 Regarding resistant hypertension the 2025 AHA/ACC G uideline states: "Based on the current BP goal of <130/80 mmHg, the prevalence of resistant hypertension is approximately 8.5% to 20% among hypertensive U.S. adults." 2 "Patients with resistant hypertension are known to have at least a 50% higher risk of MI, stroke, end-stage kidney disease, and cardiovascular death than adults with hypertension without resistance to treatment." 2 "Antihypertensive drug therapy should start with a combination of an ACEi or ARB, a CCB, and a diuretic. Replacing thiazide-type diuretics (eg, HCTZ or bendroflumethiazide) with thiazide-like diuretics (eg, chlorthalidone and indapamide) may offer additional BP reduction and cardiovascular protection among patients with previous MI or stroke." 2 Chlorthalidone's long half-life and extensive cardiovascular outcome data have made it a cornerstone of hypertension management for more than 50 years. Landmark trials such as ALLHAT and SHEP (sponsored by the National Heart, Lung and Blood Institute) demonstrated that treatment regimens based on stepped-care therapy starting with once-daily 12.5 mg chlorthalidone significantly reduced cardiovascular events.3,4 Further, previous and current guidelines recommend initiating therapy with chlorthalidone at doses of 12.5 to 25 mg, once daily.2,5 "The evidence for the benefit of low-dose chlorthalidone spans over 30 years, but unfortunately we've lacked a commercially available product that enabled widespread use of the drug effectively in practice," said Michael Ernst, PharmD, AHSCP-CHC, Clinical Professor, Department of Pharmacy Practice and Science, College of Pharmacy; and Department of Family and Community Medicine, Carver College of Medicine, The University of Iowa, Iowa City, IA. "The availability of a low-dose formulation aligns with our contemporary understanding of how to optimize the benefit-risk when using the drug, and I'm excited for this new chapter in chlorthalidone's storied history." "Chlorthalidone has played a key role in hypertension treatment strategies for decades," said William B. White, MD, Professor Emeritus at the University of Connecticut School of Medicine and past president of the American Society of Hypertension. "Having access to a 12.5 mg dose in the U.S. may offer clinicians additional flexibility when initiating therapy and aligns with current treatment recommendations for many adult patients with stage 1 or stage 2 hypertension." HemiClor® was approved by the FDA on March 17, 2025, and is now available in pharmacies nationwide. Pharmacy Savings Programs, such as SaveHealth, GoodRx, SingleCare, and WellRx, may help provide important savings to eligible patients. Using SaveHealth, for example, patients may be able to purchase a 30-day supply of HemiClor® for as little as $12.15 (price subject to change; restrictions apply; see for details). Links to external sites are provided for patient convenience only; PRM Pharma does not control or endorse their content. Indication and Usage HemiClor® (chlorthalidone) is indicated for the treatment of hypertension to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been demonstrated in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including chlorthalidone. Important Safety Information Contraindications: HemiClor® is contraindicated in patients with anuria or known hypersensitivity to chlorthalidone or sulfonamide-derived drugs. Adverse Reactions: Most common adverse reactions include electrolyte imbalance (particularly hypokalemia), dizziness, and gastrointestinal discomfort. Monitoring: Periodic monitoring of serum electrolytes is recommended. Drug Interactions: Chlorthalidone may potentiate the effects of other antihypertensive agents and may interact with lithium, antidiabetics, or NSAIDs. Please see Full Prescribing Information available at for complete efficacy and important safety information.1 To report suspected adverse reactions, contact PRM Pharma at 1-877-748-1970 or the FDA at or 1-800-FDA-1088. References: HEMICLOR® Prescribing Information. PRM Pharma, LLC. 2025. Jones OW, Ferdinand KC, Toler SJ, Johnson HM, et al. 2025 AHA/ ACC/ AANP/ AAPA/ABC/ ACCP/ ACPM/ AGS/ AMA/ ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. . Prevention of Stroke by Antihypertensive Drug Treatment in Older Patients with Isolated Systolic Hypertension Final Results at the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA. 1991;265(1):3255-3264. ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to ACE inhibitor or calcium channel blocker vs diuretic. JAMA. 2002;288(23):2981-2997. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary. Hypertension. 2018;71(6):1269-1324. *Abbreviations: BP (Blood Pressure), HCTZ (hydrochlorothiazide), ACEi (Angiotensin-Converting Enzyme Inhibitor), ARB (Angiotensin Receptor Blocker), CCB (Calcium Channel Blocker), MI (Myocardial Infarction) About PRM Pharma, LLC PRM Pharma, LLC is a privately held specialty pharmaceutical company focused on developing low-dose therapies that align with clinical practice guidelines and advance patient care. Media Inquiries: PRM Pharma, LLC – Media Relations Email: [email protected] SOURCE PRM Pharma, LLC 21% more press release views with Request a Demo

Drug Approval

29 Aug 2025

·www.einpresswire.com

April - June 2021 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)

Adcetris (brentuximab vedotin) Guillain-Barre syndrome FDA determined that no action is necessary at the time based on available information. Arzerra (ofatumumab) Gazyva (obinutuzumab) Riabni (rituximab-arrx) Rituxan (rituximab) Rituxan Hycela (rituximab and hyaluronidase human) Ruxience (rituximab-pvvr) Truxima (rituximab-abbs) Colitis FDA determined that no action is necessary at the time based on available information. Balversa (erdafitinib) Calciphylaxis The "Warnings and Precautions", "Patient Counseling Information", and the "Patient Information" sections of the labeling were updated in April 2022 to include information about soft tissue mineralization, including calciphylaxis. Balversa labeling Bavencio (avelumab) Keytruda (pembrolizumab) Opdivo (nivolumab) Yervoy (ipilimumab) Imfinzi (durvalumab) * Necrotizing fasciitis FDA determined that no action is necessary at this time based on available information. *An administrative error resulted in the omission of Imfinzi (durvalumab) from the list of product names. Imfinzi was added after the initial quarterly report was posted. Beta-blockers Betapace (sotalol hydrochloride) Brevibloc (esmolol hydrochloride) Bystolic (nebivolol) Byvalson (nebivolol and valsartan) Coreg (carvedilol) Coreg CR (carvedilol) Corgard (nadolol) Corzide (nadolol and bendroflumethiazide) Dutoprol (metoprolol succinate and hydrochlorothiazide) Kapspargo Sprinkle (metoprolol succinate) Lopressor HCT (metoprolol tartrate and hydrochlorothiazide) Sectral (acebutolol hydrochloride) Sotylize (sotalol hydrochloride) Tenoretic (atenolol and chlorthalidone) Toprol XL (metoprolol succinate) Trandate (labetalol hydrochloride) Ziac (bisoprolol fumarate and hydrochlorothiazide) Generic products containing beta-blockers Hemangeol (Propranolol Hydrochloride)* Inderal LA (Propranolol Hydrochloride)* Innopran XL (Propranolol hydrochloride)* Lopressor (metoprolol tartrate)* Tenormin (Atenolol)* Hypoglycemia in pediatric patients The "Warnings and Precautions" and "Patient Counseling Information" sections of the labeling were updated between March 2023 and June 2024 to add additional information regarding hypoglycemia. Example: Coreg labeling An administrative error resulted in the inclusion of Betapace AF, Levatol, and Zebeta in the list of product names at the time of the initial quarterly posting. *An administrative error resulted in the omission of Hemangeol, Inderal LA, Innopran XL, Lopressor, and Tenormin from the list of product names and was added after the initial quarterly report was posted. Bosulif (bosutinib monohydrate) Gleevec (imatinib mesylate) Iclusig (ponatinib) Sprycel (dasatinib) Tasigna (nilotinib) Osteonecrosis The "Adverse Reactions" section of the Tasigna labeling was updated in February 2024 to include information about osteonecrosis. Tasigna labeling FDA determined that Gleevec and Sprycel are adequately labeled for osteonecrosis, and that no further regulatory action is needed at this time. FDA determined no action is necessary at this time for Iclusig and Bosulif based on available information. Cablivi (caplacizumab-yhdp) Hemorrhage The "Warnings and Precautions", "Drug Interactions", and "Patient Counseling Information" sections of the labeling were updated in February 2022 to include information about life-threatening and fatal bleeding. Cablivi labeling Cyramza (ramucirumab) Cardiac failure The "Adverse Reactions" section of the labeling was updated in March 2022 to include information about heart failure. Cyramza labeling Doxil (doxorubicin hydrochloride) Acute interstitial pneumonitis FDA determined that no action is necessary at the time based on available information. Gleevec (imatinib mesylate) Tasigna (nilotinib) Myasthenia gravis FDA determined that no action is necessary at the time based on available information. Ibrance (palbociclib) Kisqali (ribociclib) Kisqali Femara Co-Pack (ribociclib; letrozole) Verzenio (abemaciclib) Radiation recall phenomenon FDA determined that no action is necessary at the time based on available information. Lokelma (sodium zirconium cyclosilicate) Gastrointestinal disorders FDA determined that no action is necessary at the time based on available information. Padcev (enfortumab vedotin-ejfv) Pancreatitis FDA determined that no action is necessary at the time based on available information. Padcev (enfortumab vedotin-ejfv) Pneumonitis The "Adverse Reactions", "Warnings and Precautions", and "Patient Counseling Information" sections of the labeling were updated in July 2021 to include information about pneumonitis. Padcev labeling Poteligeo (mogamulizumab-kpkc) Cytomegalovirus viraemia The "Adverse Reactions" section of the labeling was updated in March 2022 to include cytomegalovirus infection. Poteligeo labeling Procysbi (cysteamine bitartrate) Generic products containing cysteamine bitartrate Fibrosing colonopathy The "Warnings and Precautions", "Adverse Reactions", "Patient Information", and "Patient Counseling Information" sections of the labeling were updated in February 2022 to include information about fibrosing colonopathy. Example: Procysbi labeling Sarclisa (isatuximab-irfc) Herpes zoster The "Dosage and Administration", "Adverse Reactions", and "Patient Information" sections of the labeling were updated in July 2022 to include information about herpes zoster. Sarclisa labeling Sprycel (dasatinib) Drug-induced liver injury The “Warnings and Precautions”, “Adverse Reactions”, “Patient Counseling Information” and “Patient Information” sections of the labeling were updated in February 2023 to include information about hepatotoxicity. Sprycel labeling Taxotere (docetaxel) Rhabdomyolysis FDA determined that no action is necessary at the time based on available information. Veklury (remdesivir) Bradycardia FDA determined that no action is necessary at the time based on available information. Zepzelca (lurbinectedin) Extravasation The "Warnings and Precautions", "Adverse Reactions", "Patient Counseling Information", and "Patient Information" sections of the labeling were updated in April 2022 to include information about extravasation. Zepzelca labeling Zepzelca (lurbinectedin) Tumor lysis syndrome The “Adverse Reactions” section of the labeling was updated in April 2022 to include tumor lysis syndrome. Zepzelca labeling Zepzelca (lurbinectedin) Rhabdomyolysis The “Warnings and Precautions”, “Adverse Reactions”, “Patient Counseling Information”, and “Patient Information” sections of the labeling were updated in April 2022 to include rhabdomyolysis. Zepzelca labeling Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Drug Approval

100 Deals associated with Chlorthalidone

External Link

KEGG	Wiki	ATC	Drug Bank
D00272	Chlorthalidone	C03BA04	DB00310

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetes Insipidus	China	Chengdu First Pharmaceutical Co. Ltd.	01 Jan 1985
Edema	China	Chengdu First Pharmaceutical Co. Ltd.	01 Jan 1985
Nephrolithiasis	China	Chengdu First Pharmaceutical Co. Ltd.	01 Jan 1985
Hypertension	United States	Sanofi-Aventis U.S. LLC	07 Apr 1960

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02185417 (DCP, Pubmed \| J Am Heart Assoc)	Phase 3	Hypertension	3,905	Chlorthalidone 12.5/25 mg	gbwwudznny(exqylrkpfx): RR = 1.36 (95.0% CI, 0.96 - 2.12)	Negative	03 Feb 2026
				Hydrochlorothiazide 25/50 mg
NCT05411991 (DECONGEST, CTgov)	Phase 4	Volume overload \| Heart Failure \| Drug-Related Side Effects and Adverse Reactions	107	UNa measurement after intravenous loop diuretic bolus+Switch to oral diuretic therapy+Intravenous bumetanide TID+Intravenous canrenoate 200 mg OD+Intravenous acetazolamide 500 mg OD+Oral potassium supplements+chlorthalidone (Intervention Arm)	hcvpzwcymm = eanwdrbafn otnfpkxxhx (hrqgwpywyg, ctuujoudrp - iaajidlwdy) View more	-	08 Aug 2025
				Usual AHF care (Control Arm)	hcvpzwcymm = zfwobbadjs otnfpkxxhx (hrqgwpywyg, hzsbunqhnl - hpqkxijrzr) View more
ESH2025	Not Applicable	Hypertension	1,606	Chlorthalidone	xafjiyuddf(tcedvhfnyu) = evqsebqamr hepwxebxbu (ctgimcamqr ) View more	Positive	23 May 2025
				Hydrochlorothiazide	xafjiyuddf(tcedvhfnyu) = javlhtfnzn hepwxebxbu (ctgimcamqr ) View more
AD-209 (ESH2025)	Phase 2	Hypertension	221	AD-209; telmisartan 20 mg/amlodipine 2.5 mg/chlorthalidone 6.25 mg	wwruutgosr(rhiagljxes) = rtyhviopsi dzlwpabjgf (dbbjhrbtdg ) View more	Positive	23 May 2025
				AD-209-1A; telmisartan 20 mg/amlodipine 2.5 mg	svqpuudanv(wjlmqjsdip) = jxsczdiokc fydahzdzlv (towlvpsyoy )
NCT02185417 (Diuretic Comparison Project, Pubmed \| JAMA Netw Open)	Phase 3	Hypertension	-	Chlorthalidone	rkjymaxylw(nysbnwwlxw): HR = 0.94 (95% CI, 0.81 - 1.08) View more	Positive	10 Dec 2024
				Hydrochlorothiazide
NCT02841280 (CLICK, Pubmed)	Phase 2	Chronic Kidney Diseases 24-hour urinary sodium \| aldosterone \| plasma renin ... View more	160	Chlorthalidone	hhjldvadrm(zienxblmmt) = undlpbxqyh shwxtofriq (epbhhfnkbf, 25.4 - 57.4) View more	Positive	12 Jun 2024
NCT02185417 (DCP \| Diuretic Comparison Project \| Diuretic Comparison Project (DCP), CTgov)	Phase 3	Hypertension	20,723	Hydrochlorothiazide (HCTZ) (Hydrochlorothiazide)	bhikuwpkvq(ladwcyeptb) = gvnwnbcqvn gjjrfnfugl (egbndcgljl, 1.0) View more	-	22 May 2024
				Chlorthalidone (Chlorthalidone)	bhikuwpkvq(ladwcyeptb) = apeftuqqbz gjjrfnfugl (egbndcgljl, 1.0) View more
NCT02185417 (Diuretic Comparison Project (DCP), Pubmed \| JAMA Netw Open) Manual	Phase 3	Hypertension	13,523	Chlorthalidone (with prior MI or stroke at baseline)	tsaubnwuxa(cjizyziqcq) = glslhfhpyg ltupqgyabu (bajymmyfkq ) View more	Positive	01 May 2024
				Hydrochlorothiazide (with prior MI or stroke at baseline)	tsaubnwuxa(cjizyziqcq) = evqgvefgkq ltupqgyabu (bajymmyfkq ) View more
NCT02665117 (CTgov)	Not Applicable	Hypertension	61	Potassium Magnesium Citrate (KMgCit)+Chlorthalidone (KMgCit + Chlorthalidone)	ycwgpfjnjl(gvzmzrhuqv) = qwbwixxcng gjrhdlgcxx (fuvpsjoosn, 13.3) View more	-	25 Oct 2023
				Potassium Chloride (KCl)+Chlorthalidone (KCl + Chlorthalidone)	ycwgpfjnjl(gvzmzrhuqv) = xqzeiyyqeu gjrhdlgcxx (fuvpsjoosn, 9.9) View more
NCT02185417 (Diuretic Comparison Project (DCP), Pubmed \| Contemp Clin Trials)	Phase 3	Hypertension	-	Chlorthalidone	zbynwbmqbt(hddewoluhh) = ulhnnwbynv foikcrvfhf (vmzdevkevr )	-	07 Apr 2023
				Hydrochlorothiazide	zbynwbmqbt(hddewoluhh) = fgkvtnungk foikcrvfhf (vmzdevkevr )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Chlorthalidone

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation